NCT02051335 - Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Memory ImpairmentAlzheimer's Disease

Interventions

DRUG

Roflumilast

Roflumilast tablets

DRUG

Roflumilast placebo

Roflumilast placebo-matching tablets

DRUG

Donepezil

Donepezil overencapsulated tablets

DRUG

Donepezil placebo

Donepezil placebo-matching overencapsulated tablets

DRUG

Scopolamine

Scopolamine subcutaneous injection

Trial Locations (1)

London